Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d202e9e866984fe229f6facc38f1d740 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-29 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
filingDate |
1999-07-08^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1dd732b61df2587dd210076f4f5ad499 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_159ddbf3b48037d226090319b2e3f79c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a45b324343487dd895438837bd045ac http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bba3e7ef70452ff2873b27f53fd400e0 |
publicationDate |
2001-05-02^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
EP-1094844-A1 |
titleOfInvention |
Polynucleotide vaccine formulations |
abstract |
The present invention relates to a novel vaccine formulation comprising nucleic acid molecules and a mineral-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination which correlates to expression of one or more specific antigens encoded by the nucleic acid molecule. |
priorityDate |
1998-07-09^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |